

The efficacy of initial hydrocortisone administration at preventing posttraumatic distress in adult trauma patients: a randomized trial

Douglas L. Delahanty,^{1,7*} Crystal Gabert-Quillen,¹ Sarah A. Ostrowski,² Nicole R. Nugent,³ Beth Fischer,⁴ Adam Morris,¹ Roger K. Pitman,⁵ John Bon,⁶ and William Fallon, Jr.⁷

¹ Kent State University, Department of Psychology, Kent, Ohio, USA

² NeuroDevelopmental Science Center, Akron Children's Hospital, Akron, Ohio, USA

³ Alpert Brown Medical School, RIH Bradley/Hasbro Children's Research Center, Providence, Rhode Island, USA

⁴ The Center for Family Safety and Healing, Columbus, Ohio, USA

⁵ Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA

⁶ Department of Pharmacy, Summa Health System, Akron, Ohio, USA

⁷ Department of Trauma Services, Akron, Ohio, USA

Objective/Introduction. Secondary pharmacological interventions have shown promise at reducing the development of posttraumatic stress disorder symptoms (PTSS) in preclinical studies. The present study examined the preliminary efficacy of a 10-day low-dose (20 mg bid) course of hydrocortisone at preventing PTSS in traumatic injury victims.

Methods. Sixty-four traumatic injury patients (34% female) were randomly assigned in a double-blind protocol to receive either a 10-day course of hydrocortisone or placebo initiated within 12 hours of the trauma. One-month and 3-months posttrauma participants completed an interview to assess PTSS and self-report measures of depression and health-related quality of life.

Results. Hydrocortisone recipients reported fewer PTSD and depression symptoms, and had greater improvements in health-related quality of life during the first 3 months posttrauma than did placebo recipients. Hydrocortisone recipients who had never received prior mental health treatment had the lowest PTSD scores.

Conclusion. Low-dose hydrocortisone may be a promising approach to the prevention of PTSD in acutely injured trauma patients, and may be particularly efficacious in acutely injured trauma victims without a history of significant psychopathology.

Received 21 December 2012; Accepted 25 January 2013

Introduction

Population prevalence estimates of lifetime posttraumatic stress disorder (PTSD) in American adults range from 6.4–6.8%.^{1,2} A number of mental disorders and physical consequences commonly occur comorbidly with PTSD, including major depressive disorder (MDD), alcohol and drug abuse/dependence,^{3–5} suicidal ideation and suicide attempts,⁶ sleep disruption,^{7,8} and a host of medical conditions.⁹ Given negative

psychological sequelae of trauma exposure, research into the effectiveness of early intervention is necessary to determine whether the symptoms of PTSD after a traumatic event can be prevented or reduced. Early psychological interventions have been shown to be relatively ineffective and, in some cases, detrimental,^{10,11} leading researchers to examine the efficacy of early pharmacologic approaches to preventing the development of PTSD.

During the initial period of memory consolidation following a traumatic event, repetitive retrieval, reliving, and re-encoding of the event may lead to that memory becoming "overconsolidated."^{12,13} Endogenous hypercortisolemia and exogenous glucocorticoid administration has been found to impair retrieval and declarative memory performance,^{14–21} raising the possibility that therapeutic disruption of retrieval mechanisms soon after a traumatic event might protect against the development of PTSD symptoms.²²

*Address for correspondence: Douglas Delahanty, Department of Psychology, 144 Kent Hall, Kent, OH 44242, USA.
(Email: ddelahan@kent.edu)

Crystal Gabert-Quillen is now a post-doctoral fellow at Wesleyan University, Middletown, Connecticut, USA.

William Fallon, Jr. is now professor of surgery, NJMS/UMDNJ, Newark, New Jersey, USA.

Funding for this study was provided by the National Institute of Mental Health (R34 MH73014) and the Ohio Board of Regents.

Earlier research has suggested that administering hydrocortisone during septic shock or cardiac surgery leads to a decrease in the incidence of subsequent PTSD.^{23–25} However, these findings have been reported in patients in whom the cortisol may directly decrease the clinical disease, and thereby the stressfulness of the ongoing traumatic event. Recently, Zohar *et al.*²⁶ conducted a small randomized trial of the efficacy of a single high-dose (100–140 mg based on weight) bolus of hydrocortisone at preventing PTSD in mildly injured emergency department patients with acute stress symptoms. Hydrocortisone recipients ($n = 8–10$) reported significantly fewer PTSD symptoms than did placebo control patients ($n = 7–9$) at 2-week and 1- and 3-month follow-ups, suggesting the efficacy of early high-dose hydrocortisone treatment as a secondary prevention for PTSD. Given concerns of higher hydrocortisone doses impacting immune functioning and healing in injured trauma patients, we aimed to examine the efficacy of a low-dose (20 mg, twice daily: bid) 10-day course of cortisol treatment in preventing or reducing PTSD symptoms in a larger sample of more seriously injured adult traumatic injury victims. It was hypothesized that those patients receiving cortisol would be less likely to meet PTSD diagnostic criteria and would report fewer symptoms of PTSD at 1- and 3-month follow-ups than participants receiving the placebo treatment. Further, given consistent relationships between PTSD and depression^{27,28} and between PTSD and lower quality of life (QOL),^{29–32} it was hypothesized that hydrocortisone recipients would report fewer depressive symptoms and higher health-related QOL than placebo recipients. Finally, as the link between prior psychopathology and PTSD following a subsequent trauma is well-established,^{33–39} we also assessed the role of prior mental health treatment as a moderator.

Methods

Subjects

Participants consisted of 64 (34% female, 84% Caucasian, 14% African American, 2% Native American) injury victims, ranging in age from 18–56 (mean = 30.6 ± 10.7) who were admitted as trauma inpatients at a Midwestern Level-1 trauma unit. Exclusionary criteria included: Glasgow Coma Scale (GCS)⁴⁰ score of less than 14; exposure to a traumatic event that occurred more than 12 h before initial medication dose could be given or inability to initiate first medication dose within 12 h of event; allergy to cortisol or medical/medicinal contraindications to cortisol administration; pregnant or breastfeeding; exposure to a trauma of a potentially ongoing nature (e.g., domestic violence); presence of injuries requiring delayed operative

procedures; patient reported corticosteroid use in the previous 6 months; and/or patient had injuries that required treatment with steroids.

Participants were randomized to either the hydrocortisone ($n = 31$: 21 males, 10 females) or placebo ($n = 33$: 21 males, 12 females) groups. Figure 1 details participant flow through the protocol. Fifty-one participants (78%) were retained at the 1-month follow-up, and 42 (65%) were retained at the 3-month follow-up. There was no differential drop out between the hydrocortisone and placebo groups. At 1 month posttrauma, 6 participants had dropped from the placebo group and 7 had dropped from the hydrocortisone group, while at 3 months a total of 9 had dropped from the placebo group and 12 had dropped from the hydrocortisone group. Of the 13 participants who dropped between randomization and the 1-month follow-up, one complained of dizziness and asked to discontinue participation (from the hydrocortisone group), and the remaining 12 could not be contacted after numerous attempts at varying times during the day and night for at least 7 days. Drop-outs between the 1- and 3-month time points were all due to inability to reach participants after repeated attempts. There were no differences between drop-outs and participants who were retained through the protocol on any study variable. Demographic and baseline clinical data are presented in Table 1.

Procedure

The human subjects review boards of Kent State University and Summa Health System approved the following procedures.

In-hospital recruitment

All non-amnestic participants who met criterion A for exposure to a traumatic event, satisfied the inclusion criteria, and were deemed at high-risk for developing PTSD were eligible. Based on meta-analytic determination that the strongest predictor of PTSD following trauma was the presence of peritraumatic dissociation (weighted $r = .35$)⁴¹ scores on the 10-item Peritraumatic Dissociative Experiences Questionnaire Self-Report Version (PDEQ)⁴² were used to determine risk for PTSD. In previous studies, the PDEQ has been administered to trauma victims within 24 h of a traumatic event, and patients who were subsequently diagnosed with PTSD were found to have higher PDEQ scores (means scores = 3.1 ± 0.9 and 3.0 ± 0.9) than patients who did not develop PTSD (mean scores = 2.3 ± 0.6 and 2.3 ± 0.7).^{43,44} In order to target patients at high risk for PTSD, eligible participants were required to score at least a total of 27 (mean score of 2.7 per item) on the PDEQ. Following eligibility determination, participants were consented




Figure 1. Consort flow diagram of participants through the protocol.

Table 1. Frequency of demographic and study variables by group at baseline

Variable	Hydrocortisone (n = 31)	Placebo (n = 33)	Statistics
Gender			
Male	21	21	$\chi^2 = .12$
Female	10	12	
Race			
Caucasian	28	26	$\chi^2 = 3.79$
African American	2	7	
Native American	1	0	
Age mean (SD)	27.2 (8.0)	33.8 (12.0)	$F(1, 63) = 6.65^*$
Injury severity mean (SD)	4.6 (3.5)	4.5 (3.9)	$F(1, 61) = .03$
Type of trauma			
MVA	20	17	$\chi^2 = 1.33$
Fall	5	7	
Assault	4	7	
Other ^a	2	2	
Peritraumatic dissociation	36.5 (5.6)	34.5 (5.2)	$F(1, 59) = 2.15$
Peritraumatic distress	2.3 (.88)	2.3 (.97)	$F(1, 62) = .00$
Sought prior mental health treatment			
No	7	15	$\chi^2 = 3.61^{\square}$
Yes	17	12	

Note. MVA = motor vehicle accident.

^aOther = pedestrian vs. car.

[□] $p < .10$, $*p < .05$.

in-hospital and randomly assigned, in double-blind fashion, to either a 10-day course (plus a 6-day taper period) of hydrocortisone or placebo.

Medication

Following consent, the nurse administered the first oral dose [20 mg hydrocortisone (Cortef, Pharmacia) or placebo capsules] within 12 h of hospital admission. Following the protocol of Pitman *et al.*,⁴⁵ participants continued to take either the 20 mg hydrocortisone or placebo capsules every 12 h (bid) for 10 days, followed by a 6-day taper period to avoid any potential adrenal suppression. The medication regimen was tapered by halving the dose every 2 days. The 20 mg bid dose was chosen, as it reliably interferes with memory retrieval^{46,47} while having no obvious effect on wound healing or of increasing risk of infection in trauma victims.^{48–50} Higher doses of cortisol have resulted in increased infection and delayed wound healing.⁵⁰ Patient adherence to study medication was measured by diary self-reports and pill counts.

1-Month and 3-month post-injury assessments

The 1-month and 3-month follow-up assessments were identical and took place in participants' homes. Participants were administered the Clinician-Administered PTSD Scale (CAPS)⁵¹ to assess incidence of PTSD and PTSD symptoms, and were asked whether they had ever previously received help from a mental health professional. Participants were left a packet of self-report measures and a stamped envelope in which to return completed forms. Self-report measures included the Center for Epidemiological Studies—Depression Scale⁵² to assess depressive symptoms and the SF-36 to assess health-related quality of life.⁵³ At the 1-month follow-up, 33 participants (16 hydrocortisone, 17 placebo) returned the self-report instruments, while 25 participants (12 hydrocortisone, 13 placebo) returned the self-report instruments at the 3-month follow-up. There were no significant differences between participants who did and did not return self-report packets on any demographics, in-hospital assessments, or outcome variables assessed at any time point.

Measures

Peritraumatic dissociation

As mentioned, the PDEQ⁴² was used as a screener to identify individuals at high risk for developing PTSD. The PDEQ is a 10-item questionnaire designed to measure retrospective reports of derealization, depersonalization, disorientation, and altered time and body perception on 5-point scales ranging from 1 (Not at all

true) to 5 (Extremely true). The PDEQ has demonstrated reliability and validity.⁴² However, due to truncating the range of scores by requiring a minimum score of 27 to be eligible to participate, Cronbach's alpha for the present sample was .45.

Peritraumatic distress

Peritraumatic distress was assessed via the Peritraumatic Distress Inventory (PDI)⁵⁴ in order to determine whether randomization of groups was equal with regard to initial emotional responses to the trauma. The PDI demonstrated good internal consistency (alpha = 0.85) for the present study.

PTSD symptoms

PTSD severity at each follow-up was assessed with the CAPS.⁵¹ The CAPS is a structured clinical interview that provides both a dichotomous measure of PTSD incidence and a continuous measure of PTSD severity. The intensity and frequency of individual symptoms are rated on a 0 (never, not at all) to 4 (daily or almost daily, extreme) scale. Coefficient alphas were .87 and .89 at 1- and 3-month follow-ups, respectively.

Depression

The Center for Epidemiological Studies—Depression Scale (CES-D),⁵² a reliable and valid 20-item measure assessing cognitive, affective, and vegetative aspects of depression, was used to assess severity of depressive symptoms at each follow-up time point. Coefficient alphas were .82 and .77 at 1- and 3-month follow-ups, respectively.

Health-related quality of life

Health-related QOL was measured with the RAND SF-36, a standard and widely accepted measure developed in the Medical Outcomes Study (MOS).⁵² The SF-36 consists of 8 subscales; the focus of the present study was on general health. Coefficient alphas were .75 and .84 for the 1- and 3-month follow-ups, respectively.

Prior mental health treatment

Participants self-reported whether they had "ever received help from a mental health professional" at the baseline assessment.

Data Analysis

All analyses were conducted with the Statistics Package for the Social Sciences Version 19 (SPSS 2010). An alpha level of .05 (two-tailed) was used to

determine significance in all analyses. Preliminary analyses were conducted to determine normality of distributions of predictor and outcome variables. To determine potential covariates, simple differences between groups on continuous variables were evaluated using one-way analysis of variance (ANOVA), and differences between groups on categorical variables were examined with Fisher's exact tests. Next, Pearson chi-square analyses were conducted to examine group difference in PTSD diagnostic status. A series of repeated measures, or analyses of covariance (ANCOVAs), were conducted on participants who completed the entire study protocol (completer analyses) to determine whether groups differed on PTSD, depression, or QOL scores at 1 and 3 months posttrauma. Finally, two separate ANCOVAs were conducted to determine the moderating impact of previously receiving mental health treatment at 1 and 3 months, respectively. Dividing the already small sample size by whether or not participants received prior mental health treatment provided cells with insufficient numbers of participants, so separate ANCOVAs were conducted for each follow-up assessment.

Findings

Initial analyses revealed that hydrocortisone and placebo groups did not differ in race, gender, type of trauma, injury severity scores, or peritraumatic dissociation or distress (see Table 1). However, there was a significant drug group difference for age (33.8 ± 12.0 versus 27.2 ± 8.0 , for the placebo versus hydrocortisone group, respectively). Age was also significantly correlated ($r = -.30$, $p < .05$) with 1-month PTSD symptoms and was used as a covariate in subsequent analyses. Groups also marginally differed in the number of participants who had received prior mental health treatment ($\chi^2 = 3.61$, $p = .06$), with a higher percentage of participants in the hydrocortisone group receiving prior mental health treatment.

At 1 month posttrauma, 2 (8%) of the hydrocortisone recipients and 3 (11%) of the placebo recipients met full PTSD diagnostic criteria, $\chi^2(1) = .11$, $p = .75$; at 3 months, no (0%) hydrocortisone recipients and 3 (14%) placebo recipients met full PTSD diagnostic criteria, $\chi^2(1) = 2.93$, $p = .09$.

A repeated measures ANCOVA on CAPS total scores at 1 and 3 months post-trauma, covarying for age, revealed a significant main effect of time, $F(1,36) = 6.9$, $p = .01$; partial $\eta^2 = .16$, and a significant main effect of drug group, $F(1,36) = 4.0$, $p = .05$; partial $\eta^2 = .10$ (see Figure 2). PTSD symptoms decreased over time for both groups, and hydrocortisone recipients reported fewer PTSD symptoms at follow-up assessments than did placebo recipients (estimated




Figure 2. Adjusted mean CAPS total PTSD symptom scores (\pm std. error) for the placebo and hydrocortisone groups at 1 and 3 months posttrauma.

marginal means = 26.0 ± 4.0 vs. 36.5 ± 3.9 and 19.4 ± 4.0 vs. 31.3 ± 3.9 at 1- and 3-month follow-ups, respectively). The drug group \times time interaction was nonsignificant, $F(1,36) = 0.1$, $p = .74$.

In order to examine whether participants receiving prior mental health treatment (prior treatment) moderated the impact of medication group, we conducted two additional 2×2 factorial ANCOVAs with drug group and prior treatment as between subject factors, controlling for age. Results for 1 month posttrauma revealed significant main effects of drug ($F(1,46) = 7.2$, $p = .01$; partial $\eta^2 = .14$) and prior treatment groups ($F(1,46) = 6.7$, $p = .01$; partial $\eta^2 = .13$) that were qualified by a drug \times prior treatment interaction, $F(1,46) = 4.2$, $p = .05$; partial $\eta^2 = .08$. Therefore, we divided participants into those who had previously received mental health treatment ($n = 17$ hydrocortisone and 12 placebo recipients) and those who had not ($n = 7$ hydrocortisone and 15 placebo). Post hoc ANOVAs revealed no differences in PTSD scores between drug groups in those who had previously received treatment for mental health issues. However, in participants who had not previously received mental health treatment, hydrocortisone recipients reported significantly fewer PTSD symptoms than placebo recipients (15.1 versus 33.9, respectively; $F(1,20) = 4.80$, $p < .05$; see Table 2).

A similar 2×2 factorial ANCOVA was conducted on 3-month PTSD symptoms with drug group and whether the participant had received prior mental health treatment ($n = 13$ hydrocortisone and 9 placebo recipients who received prior treatment versus $n = 6$ hydrocortisone and 11 placebo who had not received prior treatment) as between subject factors, controlling for age. Results revealed a significant main effect of drug group, $F(1,34) = 4.6$, $p = .04$; partial $\eta^2 = .12$, but

Table 2. Differences in CAPS total PTSD symptom scores between placebo and hydrocortisone groups divided as to whether participants had previously sought help from a mental health professional or not

	1 month		3 months	
	No prior mental help	Yes prior mental help	No prior mental help	Yes prior mental help
Placebo	33.9 ± 20.8 ^a	33.9 ± 13.5	29.4 ± 21.9	29.2 ± 19.1
Hydrocortisone	15.1 ± 10.9 ^a	36.4 ± 13.7	14.2 ± 7.3	24.8 ± 10.3

^a Means are significant at $p < .05$.

no main effect of prior help, $F(1,34) = 0.7$, $p = .40$, or interaction effect, $F(1,34) = 1.3$, $p = .26$. This suggested that, regardless of prior mental health treatment, the hydrocortisone group (adjusted mean PTSD symptoms = 18.0) reported fewer PTSD symptoms 3 months post-trauma than the placebo group (adjusted mean = 31.0). The lack of a significant interaction effect may have reflected decreased power due to the smaller sample size at the 3-month time point.

An additional repeated measures ANCOVA on depression scores (CESD) at 1 and 3 months post-trauma, covarying for age, also revealed a significant main effect of drug group, $F(1,18) = 7.7$, $p = .01$; partial $\eta^2 = .30$ (see Figure 3), demonstrating that the hydrocortisone group reported significantly lower depression symptoms at follow-up assessments (estimated marginal means = 36.0 ± 2.2 vs. 43.6 ± 2.0 and 32.7 ± 2.7 vs. 42.5 ± 2.5 at 1- and 3-month follow-ups, respectively). Finally, an identical analysis on quality of life (SF-36) general health scores between medication groups revealed a significant drug group by time interaction, $F(1,18) = 5.3$, $p = .03$; partial $\eta^2 = .23$, suggesting that quality of life improved over time in the hydrocortisone group (from 32.6 ± 6.6 to 48.0 ± 7.7) relative to the placebo group (from 30.8 ± 6.3 to 28.3 ± 7.3).

The smaller sample sizes of participants returning self-report assessments precluded any ability to test the moderating impact of prior mental health treatment on depression and quality of life variables.

Discussion

The present study pilot tested the efficacy of a 10-day course of low-dose hydrocortisone (with 6-day taper) at preventing/buffering the development of acute posttraumatic symptoms. Hydrocortisone recipients reported fewer PTSD and depression symptoms and had greater improvements in health-related quality of life during the first 3 months posttrauma than did placebo recipients, suggesting that low-dose hydrocortisone may serve as a secondary intervention for PTSD in adult trauma victims.




Figure 3. CESD depression scores (estimated marginal means) for the placebo and hydrocortisone groups at 1 and 3 months posttrauma.

Differences in levels of PTSD symptoms reported by the hydrocortisone and placebo groups were statistically significantly different; however, as Schnurr *et al.*⁵⁵ have suggested that a 10-point difference on the CAPS is a clinically meaningful difference, the difference in CAPS symptom reporting is arguably clinically significant also. Interestingly, hydrocortisone recipients who had never received prior mental health treatment had the lowest CAPS scores, suggesting that hydrocortisone might be most efficacious in reducing PTSD symptoms in adults without significant prior psychopathology and with less complex cases of PTSD.

Despite these promising pilot findings, there are a number of limitations that suggest that the present study should be viewed with caution. Perhaps most strikingly, the present study highlights the difficulty inherent in identifying high-risk PTSD patients. Prior research has used a variety of ways of detecting individuals at increased risk for developing PTSD following trauma: initial heart rate levels,⁴⁵ a variety of questionnaires,⁵⁶ and initial PTSD symptoms.²⁶ None of these screeners was particularly effective at identifying individuals who were likely to develop PTSD. The present study used initial PDEQ score cut-offs that had previously been shown to identify individuals likely to

develop PTSD. However, the present results may not be generalizable to individuals who did not have significant peritraumatic dissociative responses. Further, our inability to reliably detect high-risk individuals underscores another major limitation to the current literature. It is difficult to demonstrate the efficacy of any early intervention if a significant percentage of participants does not develop the disorder that is meant to be intervened upon. Future research into determining reliable ways in which to identify trauma victims at risk for PTSD will lead to the targeting of limited intervention resources, as well as allow for better testing of early secondary interventions.

The present study also had a relatively small sample size with significant attrition, which is typical in recruiting traumatic injury victims. Despite the time- and labor-intensive nature of the present protocol, recruiting participants is oftentimes not difficult while they remain in the hospital. However, once participants have left the hospital and have returned to busy lives, retaining participants for follow-up assessments upon discharge poses challenges. We were fortunate in that there was no differential dropout between treatment groups, and that dropouts did not differ from retained participants on any study variable of interest at any time point.

Given the anti-inflammatory properties of hydrocortisone, an additional limitation to the current study was the failure to examine posttraumatic reports of pain as a possible mechanism accounting for the efficacy of hydrocortisone treatment. Future research should assess pain and pain medication use as potential mechanisms/moderators of the early hydrocortisone treatment.

Conclusion

Despite limitations, the present results from a randomized double-blind trial suggest that early low-dose hydrocortisone treatment may be efficacious in the prevention of PTSD in heterogeneous traumatic injury victims. This is especially promising, as the current dose was significantly lower than hydrocortisone doses examined in prior studies.^{23–26} Although future research should further examine the extent to which dose and duration alterations may improve the efficacy of hydrocortisone treatment, the present study suggests that a dose of hydrocortisone that has not been shown to impact healing may prevent posttraumatic distress in traumatic injury victims.

Disclosures

Douglas L. Delahanty, Crystal Gabert-Quillen, Sarah A. Ostrowski, Nicole R. Nugent, Adam Morris, Roger K. Pitman, and William Fallon, Jr. do not have anything to

disclose. John Bon has the following disclosures: The Medicine Company, speaker's bureau, honoraria; Merck & Co., speaker's bureau, honoraria.

References

1. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005; **62**(6): 617–627.
2. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. *J Anxiety Disord*. 2011; **25**(3): 456–465.
3. Friedman MJ, Yehuda R. Post-traumatic stress disorder and comorbidity: psychobiological approaches to differential diagnosis. In: Friedman MJ, Charney DS, Deutch AY, eds. *Neurobiological and Clinical Consequences of Stress: From Normal Adaptation to Post-Traumatic Stress Disorder*. Philadelphia: Lippincott Williams & Wilkins Publishers; 1995: 429–445.
4. Deering CG, Glover SG, Ready D, Eddleman HC, Alarcon RD. Unique patterns of comorbidity in posttraumatic stress disorder from different sources of trauma. *Compr Psychiatry*. 1996; **37**(5): 336–346.
5. Tucker P, Pfefferbaum B, Doughty DE, et al. Body handlers after terrorism in Oklahoma City: predictors of posttraumatic stress and other symptoms. *Am J Orthopsychiatry*. 2002; **72**(4): 469–475.
6. Oquendo MA, Friend JM, Halberstam B, et al. Association of comorbid posttraumatic stress disorder and major depression with greater risk for suicidal behavior. *Am J Psychiatry*. 2003; **160**: 580–582.
7. Kobayashi I, Boarts JM, Delahanty DL. Polysomnographically measured sleep abnormalities in PTSD: a meta-analytic review. *Psychophysiology*. 2007; **44**(4): 660–669.
8. Caldwell BA, Redeker N. Sleep and trauma: an overview. *Issues Ment Health Nurs*. 2005; **26**(7): 721–738.
9. Boscarino JA. Posttraumatic stress disorder and physical illness: results from clinical and epidemiologic studies. In: Yehuda R, McEwen B, eds. *Biobehavioral Stress Response: Protective and Damaging Effects*. New York: New York Academy of Sciences; 2004: 141–153.
10. Mayou R, Ehlers A, Hobbs M. Psychological debriefing for road traffic accident victims: three-year follow-up of a randomised controlled trial. *Br J Psychiatry*. 2000; **176**: 589–593.
11. Rose S, Brewin CR, Andrews B, et al. A randomized controlled trial of individual psychological debriefing for victims of violent crime. *Psychol Med*. 1999; **29**: 793–799.
12. Larkin M. Can post-traumatic stress disorder be put on hold? *Lancet*. 1999; **354**: 1008.
13. Pitman RK. Post-traumatic stress disorder, hormones, and memory. *Biol Psychiatry*. 1989; **26**: 221–223.
14. de Quervain DJ, Henke K, Aerni A, et al. Glucocorticoid-induced impairment of declarative memory retrieval is

- associated with reduced blood flow in the medial temporal lobe. *Eur J Neurosci.* 2003; **17**(6): 1296–1302.
15. Kirschbaum C, Wolf OT, May M, Wippich W, Hellhammer DH. Stress- and treatment-induced elevations of cortisol levels associated with impaired declarative memory in healthy adults. *Life Sci.* 1996; **58**: 1475–1483.
 16. Mauri M, Sinforiani E, Bono G, et al. Memory impairment in Cushing's disease. *Acta Neurol Scand.* 1993; **87**: 52–55.
 17. Newcomer JW, Craft S, Hershey T, Askins K, Bardgett ME. Glucocorticoid-induced impairment in declarative memory performance in adult humans. *J. Neurosci.* 1994; **14**: 2047–2053.
 18. Newcomer JW, Selke G, Melson AK, et al. Decreased memory performance in healthy humans induced by stress-level cortisol treatment. *Arch Gen Psychiatry.* 1999; **56**: 527–533.
 19. Wolkowitz OM, Reus VI, Weingartner H, et al. Cognitive effects of corticosteroids. *Am J Psychiatry.* 1990; **147**: 1297–1303.
 20. Lupien SJ, McEwen BS. The acute effects of corticosteroids on cognition: integration of animal and human model studies. *Brain Res Rev.* 1997; **24**: 1–27.
 21. Martignoni E, Costa A, Sinforiani E, et al. The brain as a target for adrenocortical steroids: cognitive implications. *Psychoneuroendocrinology.* 1992; **17**(1): 343–354.
 22. deQuervain DJ, Aerni A, Schelling G, Roozendaal B. Glucocorticoids and the regulation of memory in health and disease. *Front Neuroendocrinol.* 2009; **30**: 358–370.
 23. Schelling G, Stoll C, Kapfhammer HP, et al. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder and health-related quality of life in survivors. *Crit Care Med.* 1999; **27**: 2678–2683.
 24. Schelling G, Briegel J, Roozendaal B, et al. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. *Biol Psychiatry.* 2001; **50**: 978–985.
 25. Schelling G, Kilger E, Roozendaal B, et al. Stress doses of hydrocortisone, traumatic memories and post-traumatic stress disorder in patients after cardiac surgery: a randomized study. *Biol. Psychiatry.* 2004; **55**: 627–633.
 26. Zohar J, Yahalom H, Kozlovsky N, et al. High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: interplay between clinical and animal studies. *Eur Neuropsychopharmacol.* 2011; **21**(11): 796–809.
 27. Breslau N, Davis GC, Peterson EL, Schultz LR. A second look at comorbidity in victims of trauma: the posttraumatic stress disorder–major depression connection. *Biol Psychiatry.* 2000; **48**: 902–909.
 28. Campbell DG, Felker BL, Liu C, et al. Prevalence of depression–PTSD comorbidity: implications for clinical practice guidelines and primary care-based interventions. *J Gen Intern Med.* 2007; **22**(6): 711–718.
 29. Clark DB, Kirisci L. PTSD, depression, and adolescent alcohol use disorders and quality of life in adolescents. *Anxiety.* 1996; **2**: 226–233.
 30. Eisenman DP, Gelberg L, Liu H, Shapiro MF. Mental health and health-related quality of life among adult Latino primary care patients living in the United States with previous exposure to political violence. *JAMA.* 2003; **290**: 627–634.
 31. Warshaw MG, Fierman E, Pratt L, et al. Quality of life and dissociation in anxiety disorder patients with histories of trauma or PTSD. *Am J Psychiatry.* 1993; **150**(10): 1512–1516.
 32. Zatzick DF, Marmur CR, Weiss DS, et al. Posttraumatic stress disorder and functioning and quality of life outcomes in a nationally representative sample of male Vietnam veterans. *Am J Psychiatry.* 1997; **154**: 1690–1695.
 33. Blanchard EB, Hickling EJ, Taylor AE, et al. Who develops PTSD from motor vehicle accidents? *Behav Res Ther.* 1996; **34**(1): 1–10.
 34. Blanchard EB, Hickling EJ, Taylor AE, Loos W, Gerardi RJ. Psychological morbidity associated with motor vehicle accidents. *Behav Res Ther.* 1994; **3**: 283–290.
 35. Breslau N, Davis GC. Posttraumatic stress disorder in an urban population of young adults: risk factors for chronicity. *Am J Psychiatry.* 1992; **149**(5): 671–675.
 36. McFarlane AC. The etiology of post-traumatic morbidity: predisposing, precipitating and perpetuating factors. *Br J Psychol.* 1989; **154**: 221–228.
 37. Shalev AY, Freedman A, Peri T, et al. Prospective study of posttraumatic stress disorder and depression following trauma. *Am J Psychiatry.* 1998; **155**(5): 630–637.
 38. Ullman SE, Siegel JM. Predictors of exposure to traumatic events and posttraumatic stress sequelae. *J Community Psychol.* 1994; **22**: 328–338.
 39. Ursano RJ, Fullerton CS, Epstein RS, et al. Acute and chronic posttraumatic stress disorder in motor vehicle accident victims. *Am J Psychiatry.* 1999; **156**: 589–595.
 40. Teasdale G, Jennett B. Assessment of coma and impaired consciousness: a practical scale. *Lancet.* 1974; **2**: 81–84.
 41. Ozer EJ, Best SR, Lipsey TL, Weiss DS. Predictors of posttraumatic stress disorder and symptoms in adults. *Psychol Bull.* 2003; **129**(1): 52–73.
 42. Marmar CR, Weiss DS, Metzler TJ. The Peritraumatic Dissociative Experiences Questionnaire. In: Wilson JP, Keane TM, eds. *Assessing Psychological Trauma PTSD*, 1st ed. New York: Guilford; 1997: 412–428.
 43. Birmes P, Brunet A, Carreras D, et al. The predictive power of peritraumatic dissociation and acute stress symptoms for posttraumatic stress symptoms: a three month prospective study. *Am J Psychiatry.* 2003; **160**: 1337–1339.
 44. Birmes P, Carreras D, Charlet J-P, et al. Peritraumatic dissociation and posttraumatic stress disorder in victims of violent assault. *J Nerv Ment Dis.* 2001; **189**: 796–798.
 45. Pitman RK, Sanders KM, Zusman RM, et al. Pilot study of secondary prevention for posttraumatic stress disorder with propranolol. *Biol Psychiatry.* 2002; **51**: 189–192.
 46. de Quervain DJ, Roozendaal B, Nitsch RM, McGaugh JL, Hock C. Acute cortisone administration impairs retrieval of long-term declarative memory in humans. *Nat Neurosci.* 2000; **3**(4): 313–314.

47. Kirschbaum C, Wolf OT, May M, Wippich W, Hellhammer DH. Stress- and treatment-induced elevations of cortisol levels associated with impaired declarative memory in healthy adults. *Life Sci.* 1996; **58**: 1475–1483.
48. DiPasquale G, Steinetz BG. Relationship of food intake to the effect of cortisone acetate on skin wound healing. *Proc Soc Exp Biol Med.* 1964; **117**: 118–120.
49. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. *Ann Intern Med.* 1976; **84**(3): 304–315.
50. Anstead GM. Steroids, retinoids, and wound healing. *Adv Wound Care.* 1998; **11**: 277–285.
51. Blake DD, Weathers FW, Nagy LM, *et al.* The development of a clinician-administered PTSD scale. *J Trauma Stress.* 1995; **8**(1): 75–90.
52. Radloff LS. The CES-D scale: a new self-report depression scale for research in the general population. *Appl Psychol Meas.* 1977; **1**: 385–401.
53. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36): conceptual framework and item selection. *Med Care.* 1992; **30**(6): 473–483.
54. Brunet A, Weiss DS, Metzler TJ, *et al.* The Peritraumatic Distress Inventory: a proposed measure of PTSD criterion A2. *Am J Psychiatry.* 2001; **158**: 1480–1485.
55. Schnurr PP, Friedman MJ, Foy DW, *et al.* Randomized trial of trauma-focused group therapy for posttraumatic stress disorder: results from a Department of Veterans' Affairs cooperative study. *Arch Gen Psychiatry.* 2003; **60**: 481–489.
56. Winston FA, Kassam-Adams N, Garcia-Espana F, Ittenbach R, Cnaan A. Screening for risk of persistent posttraumatic stress in injured children and their parents. *JAMA.* 2003; **290**: 643–649.